Bank of New York Mellon Corp lessened its holdings in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 5.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 573,063 shares of the company's stock after selling 34,852 shares during the quarter. Bank of New York Mellon Corp owned 0.64% of DaVita worth $47,432,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ellevest Inc. increased its position in DaVita by 1,388.0% during the 3rd quarter. Ellevest Inc. now owns 372 shares of the company's stock worth $31,000 after purchasing an additional 347 shares in the last quarter. Eisler Capital UK Ltd. acquired a new stake in DaVita during the 3rd quarter worth approximately $35,000. Parkside Financial Bank & Trust grew its position in DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company's stock valued at $35,000 after acquiring an additional 147 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in DaVita in the third quarter valued at approximately $40,000. Finally, Wipfli Financial Advisors LLC acquired a new stake in DaVita in the third quarter valued at approximately $44,000. Institutional investors and hedge funds own 86.52% of the company's stock.
Get DaVita alerts:DaVita Stock Performance
DaVita stock opened at $76.12 on Friday. The stock has a 50 day moving average of $80.61 and a 200-day moving average of $80.17. DaVita Inc. has a 52 week low of $65.28 and a 52 week high of $124.81. The stock has a market cap of $6.88 billion, a P/E ratio of 13.17, a price-to-earnings-growth ratio of 1.57 and a beta of 0.95. The company has a current ratio of 1.20, a quick ratio of 1.16 and a debt-to-equity ratio of 9.92.
DaVita (NYSE:DVA – Get Rating) last announced its quarterly earnings data on Wednesday, February 22nd. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.23. DaVita had a return on equity of 74.02% and a net margin of 4.83%. The firm had revenue of $2.92 billion for the quarter, compared to analysts' expectations of $2.93 billion. During the same period last year, the business posted $2.02 earnings per share. The firm's revenue for the quarter was down .9% on a year-over-year basis. On average, analysts expect that DaVita Inc. will post 5.93 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have issued reports on DVA shares. StockNews.com started coverage on shares of DaVita in a research report on Thursday, March 16th. They issued a "buy" rating for the company. Truist Financial increased their price objective on shares of DaVita from $84.00 to $90.00 and gave the company a "hold" rating in a research report on Thursday, February 23rd. Sanford C. Bernstein started coverage on shares of DaVita in a research report on Tuesday, March 7th. They issued a "market perform" rating for the company. Cowen increased their price objective on shares of DaVita from $76.00 to $90.00 and gave the company an "outperform" rating in a research report on Thursday, February 23rd. Finally, Deutsche Bank Aktiengesellschaft increased their target price on DaVita from $72.00 to $85.00 in a research note on Thursday, February 23rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $86.43.
Insider Buying and Selling
In related news, Director Charles Berg sold 1,431 shares of the firm's stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $75.13, for a total transaction of $107,511.03. Following the transaction, the director now directly owns 15,733 shares in the company, valued at $1,182,020.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by company insiders.
DaVita Company Profile
(Get Rating)
DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
Featured Articles
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 5 Best Dividend Capture Stocks
- 10 Best Consumer Discretionary ETFs
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.